Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

An Open-Label, Single Center Study Evaluating the Safety, Tolerability, and Immunogenicity of Cizutamig for Patients With Moderate to Severe Ulcerative Colitis

NCT07353450 is registered in ClinicalTrials.gov with Ruijin Hospital as lead sponsor.

NCT NCT07353450
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07353450 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
An Open-Label, Single Center Study Evaluating the Safety, Tolerability, and Immunogenicity of Cizutamig for Patients With Moderate to Severe Ulcerative Colitis
Lead sponsor
Ruijin Hospital
Phase
Phase 1
Overall status
Not yet recruiting
Start date
January 31, 2026
Completion date
December 31, 2027
Enrollment
15 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

ulcerative colitis (uc)